Tony Yu

20+ years in biotech/biopharma industry, with expertise in oncology and biologics: starting as a scientist (first employee of the company) developing oncolytic virus and bacteria as live biologic drug products for cancer diagnosis and immunotherapy in human and veterinarian medicine, growing along with the company from department director to Associate VP and to VP. Currently leading Phase I, II & III clinical development in the US and Europe (UK and Germany) as VP of Clinical Trial Operations. Closely interact with regulatory agencies (FDA, USDA & NIH OBA of the US, MHRA of UK, PEI of Germany, etc.), large academic (e.g. Stanford School of Medicine, UCSD & Moores Cancer Center, NIH, Dana Farber Cancer Institute/Harvard Medical School, University of Tuebingen, University of Wuerzburg, University of Leeds, University of Surrey, Institute of Cancer Research UK, etc.) and institutions (e.g., Memorial Sloan-Kettering Cancer Center, California Veterinary Specialists, University Clinic Tuebingen, Royal Marsden Hospital, Royal Surrey County Hospital, Florida Hospital, etc.), CROs, biotech and pharmaceutical companies, and key opinion leaders. Represent the company and present clinical and preclinical data in conferences and business partnership/licensing meetings.